SecBot SecBot
Biotech Drug Report Generated Sep 12, 2026

ABO-701

ABEO·ABEONA THERAPEUTICS INC.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical
Time to market
Unknown, at least 4-6 years away if clinical trials succeed. IND filing is expected H2 2027, followed by Phase 1/2 trials that typically take 2-3 years, then pivotal trials.
Why 2/10
ABO-701 is preclinical with no hard, dated catalyst within the next ~12 months (IND filing expected H2 2027). It is a small pipeline asset at a company whose primary value driver is the already-approved, commercial-stage ZEVASKYN. Even a positive IND update would be a modest catalyst relative to the company's commercial execution story.
Actionable Insight NEUTRAL

ABO-701 is too early-stage (preclinical, IND expected H2 2027) to drive ABEO's share price in the next 12 months. Investors should focus on ZEVASKYN commercial execution (patient treatment volumes, revenue growth, manufacturing yields) as the primary near-term value driver. Any ABO-701-related moves would be speculative and tied to broader pipeline sentiment rather than a hard catalyst.

Price Chart

Loading chart...

Executive Summary

ABO-701 (PSMA-SIR-T) is a preclinical gene therapy candidate for prostate cancer that Abeona Therapeutics in-licensed in Q1 2026 for a $7.0M upfront payment. It uses a PSMA-targeted approach to deliver a gene therapy payload to prostate cancer cells. The drug remains in preclinical development with an IND filing expected in the second half of 2027, more than 12 months away. Abeona's primary value driver is ZEVASKYN, its already-approved and commercializing gene therapy for epidermolysis bullosa, which generated $11.4M in Q2 2026 revenue. ABO-701 is a small, early-stage pipeline asset with no near-term binary catalyst, making it a negligible factor for the stock in the next 12 months.

How It Works

ABO-701 is a gene therapy designed to target prostate cancer cells. It uses a modified virus (AAV vector) to deliver a therapeutic gene specifically to cells that express PSMA, a protein found at high levels on the surface of prostate cancer cells. The therapy is designed to enter those cancer cells and trigger an anti-tumor effect, essentially reprogramming the cancer cells to self-destruct or become visible to the immune system.

Trial Status

ABO-701 is in preclinical development. It was in-licensed by Abeona in Q1 2026 for a $7.0M upfront payment. The company expects to file an Investigational New Drug (IND) application with the FDA in the second half of 2027. No clinical trials have been initiated yet.

The Two-Sided Case

▲ Bull Case3
PSMA is a well-validated target in prostate cancer, and a gene therapy approach could offer a novel treatment option if clinical data support it.
Abeona has gene therapy expertise from ZEVASKYN (already approved), which could accelerate ABO-701 development.
Analyst consensus is strongly bullish on ABEO (11 Buy/Strong Buy vs 1 Hold), with a mean price target of $18.86 implying ~214% upside from ~$5.42.
▼ Bear Case5
ABO-701 is preclinical, no clinical data exist yet. Most preclinical candidates never make it to approval.
IND filing is not expected until H2 2027, meaning no near-term catalyst for at least 12+ months.
Abeona's cash burn ($44.6M in H1 2026) and $146.8M remaining cash may require additional financing before ABO-701 reaches the clinic.
The $7.0M in-licensing fee adds to R&D spend for a program with no near-term revenue potential.
A law firm (Pomerantz) is investigating claims on behalf of ABEO investors, adding legal overhang.

Upcoming Catalysts

  • IND filing expected H2 2027 (more than 12 months out)
  • No near-term binary catalysts for ABO-701 specifically

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ABEONA THERAPEUTICS INC. 8-K ABEO ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 globenewswire.com3 globenewswire.com4 prnewswire.com